Journal of Hematology and Oncology Q1 Unclaimed
Journal of Hematology and Oncology is a journal indexed in SJR in Molecular Biology and Hematology with an H index of 144. It is an CC BY Journal with a Single blind Peer Review review system, and It has a price of 1815 €. The scope of the journal is focused on haematology, oncology. It has an SJR impact factor of 7,522 and it has a best quartile of Q1. It is published in English. It has an SJR impact factor of 7,522.
Journal of Hematology and Oncology focuses its scope in these topics and keywords: biomarkers, progression, pathwayssmi, pathways, pathogenesis, nsclc, nktldownstream, natural, myeloid, proliferative, ...
Type: Journal
Type of Copyright: CC BY
Languages: English
Open Access Policy: Open Access
Type of publications:
Publication frecuency: -
1815 €
Inmediate OANPD
Embargoed OA- €
Non OAMetrics
7,522
SJR Impact factor144
H Index115
Total Docs (Last Year)531
Total Docs (3 years)11441
Total Refs12065
Total Cites (3 years)413
Citable Docs (3 years)20.83
Cites/Doc (2 years)99.49
Ref/DocOther journals with similar parameters
Cell Research Q1
Molecular Cell Q1
Cell Host and Microbe Q1
Annual Review of Plant Biology Q1
Nature Protocols Q1
Compare this journals
Aims and Scope
Best articles by citations
Ferroptosis, a new form of cell death: opportunities and challenges in cancer
Tumor-associated macrophages in tumor metastasis: biological roles and clinical therapeutic applications
The biology and role of CD44 in cancer progression: therapeutic implications
Ferroptosis, necroptosis, and pyroptosis in anticancer immunity
Nanomaterials for cancer therapy: current progress and perspectives
Tumor-associated macrophages: from basic research to clinical application
Targeting mitochondrial reactive oxygen species as novel therapy for inflammatory diseases and cancers
Cancer-associated fibroblasts: an emerging target of anti-cancer immunotherapy
Next generation of immune checkpoint therapy in cancer: new developments and challenges
Exosomes derived from miR-122-modified adipose tissue-derived MSCs increase chemosensitivity of hepatocellular carcinoma
SARS-CoV-2 binds platelet ACE2 to enhance thrombosis in COVID-19
Immune checkpoint inhibitors of PD-L1 as cancer therapeutics
Wnt/beta-catenin pathway: modulating anticancer immune response
Tumor-derived exosomal miR-934 induces macrophage M2 polarization to promote liver metastasis of colorectal cancer
Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy
Role of platelets and platelet receptors in cancer metastasis
The interplay between m6A RNA methylation and noncoding RNA in cancer
A phase 1, open-label study of LCAR-B38M, a chimeric antigen receptor T cell therapy directed against B cell maturation antigen, in patients with relapsed or refractory multiple myeloma
NK cell-based cancer immunotherapy: from basic biology to clinical development
Anlotinib: a novel multi-targeting tyrosine kinase inhibitor in clinical development
Comments